Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 19/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 17/20 | 0.89 |
| ▸ | TP53 | P04637 | 9/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077268 | 0.94 | MAPT (1.00) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL19569163 | 0.91 | MAPT (0.83) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL2253797 | 0.83 | MAPT (0.70) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL31344107 | 0.82 | MAPT (1.00) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL10077294 | 0.82 | MAPT (1.00) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL10077260 | 0.82 | MAPT (1.00) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL2252198 | 0.81 | MAPT (0.78) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL31344185 | 0.80 | MAPT (0.79) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL10077283 | 0.80 | GAA (1.00) | MAPTSMN1; SMN2GAATP53KDM4E | |
| SCHEMBL2254207 | 0.79 | MAPT (0.70) | MAPTSMN1; SMN2GAATP53KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065251-B2 | PAK1 inhibitors and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2017192228-A1 | PAK1 INHIBITORS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065251-B2 | PAK1 inhibitors and uses thereof | PAK1, CDC42, CDC42BPG | MAPT 3472/4885SMN1; SMN2 3178/4885GAA 3778/4885 |
| US-20200323855-A1 | PAK1 INHIBITORS AND USES THEREOF | PAK1, CDC42, CDC42BPG | MAPT 3472/4885SMN1; SMN2 3178/4885GAA 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.